Recent studies showed that tumor cells 'edit'host immunity in several ways to evade immune
defenses in the tumor microenvironment. This phenomenon is called “cancer immune …

The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid
malignancies provided proof-of-principle for exploiting the immune system therapeutically …

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve
prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody …

Immunotherapeutic strategies are emerging as promising therapeutic approaches in
multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical …

Tumour-induced dysfunction of cytotoxic T cells in patients with multiple myeloma (MM) may
contribute to immune escape and be responsible for the lack of therapeutic efficacy of …

Bispecific T‐cell engager (Bi TE®) antibody constructs represent a novel immunotherapy
that bridges cytotoxic T cells to tumor cells, thereby inducing target cell‐dependent …

The present invention provides isolated monoclonal antibodies, particularly human
monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid …

The present invention provides isolated monoclonal antibodies, particularly human
monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid …

Related US Application Data (62) Division of application No. 12/959,307, filed on Dec. 2,
2010, now Pat. No. 8,728,474, which is a division of application No. 12/538,698, filed on …

The treatment landscape for patients with multiple myeloma (MM) is constantly evolving.
Over the past decade, the introduction of novel agents such as proteasome inhibitors and …